Breaking News Instant updates and real-time market news.

OMER

Omeros

$21.29

0.49 (2.36%)

11:21
08/23/17
08/23
11:21
08/23/17
11:21

Omeros responding to 'correct some of the inaccuracies' in Statnews.com story

Omeros Corporation stated that it continues to pursue legal action to hold responsible those behind a series of defamatory reports about the company posted online under the pseudonym "Art Doyle," an entity or group that self-identifies as having a short position in Omeros' stock. "Because of its ongoing legal action, including a number of steps aimed at unmasking the identity of the individual(s) responsible, Omeros elected not to respond to queries from a writer for statnews.com who evidently had early access to and commented through Twitter on the initial "Art Doyle" false report before it was broadly made public. While, for the reason stated above, Omeros will not engage in a running dialogue with this writer, the company will respond this one time to correct some of the inaccuracies in yesterday's statnews.com story," the company said. Additionally, Omeros said: "As of June 30, 2017, 54 patients had been enrolled in OMS721 Phase 2 clinical trials. Since then, the enrollment number has continued to increase. Presentations of OMS721 clinical data at international scientific meetings span February 2017 through June 2017. These presentations are directed to respective groups of patients and are not intended to reflect total patient counts. In addition, like most biopharmaceutical companies, Omeros does not routinely release all clinical data as they are generated. As noted in the company's press release dated August 4, 2017, more than 150 subjects had been dosed with OMS721, and that number continues to increase. On March 16, 2017, Omeros publicly announced that enrollment had opened for its Phase 3 clinical trial evaluating OMS721 in patients with atypical hemolytic uremic syndrome, or aHUS. In connection with this study and consistent with regulations governing clinicaltrials.gov postings, a clinicaltrials.gov filing was made by the company on April 17, 2017. This date, as recorded by the website administrators at the National Institutes of Health, is found on the clinicaltrials.gov summary for this Phase 3 trial. The estimated completion date of the aHUS Phase 3 clinical trial for approximately 80 patients is listed as 2020 on clinicaltrials.gov. The posting on clinicaltrials.gov also clearly states that an interim analysis will be conducted following treatment of approximately 40 patients for potential submission for regulatory approval. This is consistent with Omeros' publicly available statements that, based on discussions with both FDA and the European Medicines Agency, the company received guidance from those regulatory bodies that 40 patients may be sufficient for accelerated approval in the U.S. and for full approval in Europe...Omeros, for competitive reasons and consistent with common practice in the industry, has not released any PK/PD data."

OMER Omeros
$21.29

0.49 (2.36%)

05/11/17
CANT
05/11/17
DOWNGRADE
Target $15
CANT
Neutral
Omeros downgraded to Neutral from Overweight at Cantor
Cantor analyst Elemer Piros downgraded Omeros to Neutral and lowered its price target to $15 from $21 following the slightly weaker than expected Q1 report. The analyst has tempered his estimates for the US commercial ramp in peak market penetration to 25% from 30% and views shares as fully valued.

TODAY'S FREE FLY STORIES

JUNO

Juno Therapeutics

$69.25

23.65 (51.86%)

, CELG

Celgene

$102.02

-2.8 (-2.67%)

07:03
01/18/18
01/18
07:03
01/18/18
07:03
Downgrade
Juno Therapeutics, Celgene rating change  »

Juno Therapeutics…

JUNO

Juno Therapeutics

$69.25

23.65 (51.86%)

CELG

Celgene

$102.02

-2.8 (-2.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

CSII

Cardiovascular Systems

$26.24

0.91 (3.59%)

07:02
01/18/18
01/18
07:02
01/18/18
07:02
Hot Stocks
Cardiovascular Systems partners with OrbusNeich, forms OEM agreement »

Cardiovascular Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

SPX

S&P 500

07:02
01/18/18
01/18
07:02
01/18/18
07:02
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGEN

Compugen

$2.75

0.25 (10.00%)

07:02
01/18/18
01/18
07:02
01/18/18
07:02
Hot Stocks
Compugen presents new data demonstrating features of the PVRIG pathway »

Compugen announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$50.27

0.68 (1.37%)

, PANW

Palo Alto Networks

$154.23

2.63 (1.73%)

07:01
01/18/18
01/18
07:01
01/18/18
07:01
Recommendations
Oracle, Palo Alto Networks, Apptio, Alarm.com, Nice, Symantec, RingCentral, Splunk, VMware analyst commentary  »

Jefferies sees more…

ORCL

Oracle

$50.27

0.68 (1.37%)

PANW

Palo Alto Networks

$154.23

2.63 (1.73%)

APTI

Apptio

$24.00

0.29 (1.22%)

ALRM

Alarm.com

$38.27

1.26 (3.40%)

NICE

Nice

$92.63

0.67 (0.73%)

SYMC

Symantec

$27.52

-0.35 (-1.26%)

RNG

RingCentral

$51.50

0.85 (1.68%)

SPLK

Splunk

$90.57

3.44 (3.95%)

VMW

VMware

$135.33

3.19 (2.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 31

    Jan

  • 05

    Feb

  • 26

    Feb

  • 27

    Feb

AES

AES Corp.

$10.72

0.04 (0.37%)

07:01
01/18/18
01/18
07:01
01/18/18
07:01
Hot Stocks
AES Corp. names ValueAct CEO Jeffrey Ubben to board »

The AES Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$160.21

2.25 (1.42%)

07:00
01/18/18
01/18
07:00
01/18/18
07:00
Hot Stocks
Accenture awarded $62M contract with Veterans Benefits Administration »

Accenture has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$55.35

0.75 (1.37%)

06:59
01/18/18
01/18
06:59
01/18/18
06:59
Hot Stocks
Morgan Stanley reports Common Equity Tier 1 ratio approximately 16.5% »

As of December 31, 2017,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

GDX

Market Vector Gold Miners

$23.94

-0.43 (-1.76%)

06:58
01/18/18
01/18
06:58
01/18/18
06:58
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$55.34

0.75 (1.37%)

06:58
01/18/18
01/18
06:58
01/18/18
06:58
Hot Stocks
Morgan Stanley reports total client assets were $2.4T at Q4-end »

Total client assets were…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

GLD

SPDR Gold Trust

$126.14

-1.03 (-0.81%)

06:58
01/18/18
01/18
06:58
01/18/18
06:58
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

R

Ryder

$88.98

0.46 (0.52%)

06:57
01/18/18
01/18
06:57
01/18/18
06:57
Hot Stocks
Ryder appoints Rajeev Ravindran Chief Information Officer »

Ryder appointed Rajeev…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

NUGT

Direxion Gold Miners Bull

$34.40

-1.75 (-4.84%)

06:57
01/18/18
01/18
06:57
01/18/18
06:57
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$55.35

0.75 (1.37%)

06:56
01/18/18
01/18
06:56
01/18/18
06:56
Hot Stocks
Morgan Stanley CEO: We enter 2018 with strong momentum »

James P. Gorman, Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$18.83

-0.99 (-5.00%)

06:56
01/18/18
01/18
06:56
01/18/18
06:56
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUST

Direxion Daily Gold Miners Bear 3X ETF

$21.38

1.07 (5.27%)

06:55
01/18/18
01/18
06:55
01/18/18
06:55
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$351.01

15.85 (4.73%)

06:55
01/18/18
01/18
06:55
01/18/18
06:55
Periodicals
Lawmakers question safety of SpaceX, Boeing internal helium tanks, WSJ reports »

The National Aeronautics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

MS

Morgan Stanley

$55.34

0.75 (1.37%)

06:55
01/18/18
01/18
06:55
01/18/18
06:55
Earnings
Morgan Stanley reports Q4 EPS 84c, consensus 77c »

Reports Q4 revenue $9.5B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$46.85

2.29 (5.14%)

06:55
01/18/18
01/18
06:55
01/18/18
06:55
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VXX

iPath S&P 500 VIX Short-Term Futures

$26.83

-0.61 (-2.22%)

06:54
01/18/18
01/18
06:54
01/18/18
06:54
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPG

PPG

$114.50

-2.14 (-1.83%)

06:54
01/18/18
01/18
06:54
01/18/18
06:54
Hot Stocks
PPG committed to deploy at least $2.4B on acquisitions, repurchases in 2018 »

"Looking ahead, we…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

PPG

PPG

$114.50

-2.14 (-1.83%)

06:53
01/18/18
01/18
06:53
01/18/18
06:53
Hot Stocks
PPG sees FY18 effective tax rate 23%-24% »

With the enactment of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

XIV

VelocityShares Daily Inverse VIX Short-Term ETN

$140.73

2.97 (2.16%)

06:53
01/18/18
01/18
06:53
01/18/18
06:53
Technical Analysis
VelocityShares Daily Inverse VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVIX

VelocityShares Daily 2x VIX Short-Term ETN

$5.09

-0.25 (-4.68%)

06:52
01/18/18
01/18
06:52
01/18/18
06:52
Technical Analysis
VelocityShares Daily 2x VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPG

PPG

$114.50

-2.14 (-1.83%)

06:52
01/18/18
01/18
06:52
01/18/18
06:52
Hot Stocks
Breaking Hot Stocks news story on PPG »

PPG committed to deploy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.